Healthcare / BiotechnologyNasdaqGM
$2.61
-0.09 (-3.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-37.0M · quality 54.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$378M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-24.3%
↓Gross Margin
98.4%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
-14.4%
FCF CAGR
—
FCF margin
-198.3%
FCF / Net income
0.57x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $18.7M · net income $-64.8M · FCF $-37.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | $18.7M | $18.7M | $26.4M | $34.2M | $59.1M | $34.7M |
| Net Income | $-64.8M | $-64.8M | $-62.0M | $-50.6M | $-22.3M | $-27.0M |
| EBITDA | $-47.2M | $-47.2M | $-50.9M | $-49.9M | $-8.4M | $-19.4M |
| EPS | -0.57 | -0.57 | -0.61 | -0.51 | -0.26 | -0.33 |
| Gross Margin | 98.4% | 98.4% | 100.0% | — | — | — |
| Operating Margin | -369.5% | -369.5% | -282.3% | -203.2% | -45.1% | -102.5% |
| Net Margin | -347.0% | -347.0% | -235.1% | -148.2% | -37.8% | -77.8% |
| Balance Sheet | ||||||
| Debt/Equity | 0.08 | 0.08 | 0.08 | 0.08 | 0.08 | — |
| Current Ratio | 4.80 | 4.80 | — | — | — | — |
| Cash Flow | ||||||
| Free Cash Flow | $-37.0M | $-37.0M | $-41.5M | $703000.00 | $-20.8M | $-9.7M |
| Returns | ||||||
| ROE | -24.3% | -24.3% | -21.6% | -16.1% | -6.5% | -11.5% |
| Valuation | ||||||
| P/B | 1.11 | 1.11 | 1.31 | 2.04 | 0.83 | — |
| Growth & Yield | ||||||
| Revenue Growth | -29.3% | -29.3% | -22.8% | -42.2% | — | — |
| EPS Growth | 6.6% | 6.6% | -19.6% | -96.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+105.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.61 → -0.57
Residual
+105.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.